Differentiated thyroid cancer (DTC) with minimal extrathyroidal extension (MEE) is classified as stage III regardless of the tumor size. In this study, we aim to examine the effect of MEE on the overall survival and management of this population. A retrospective cohort study was performed, which utilized the National Cancer Database (NCDB), 2004-2012. The study population included patients, aged ≥ 45 years, who underwent surgery for DTC (pT3N0M0) with MEE compared to that in patients with pT2N0M0.
Introduction
Thyroid capsule invasion by the primary tumor is suggested to reflect disease prognosis (Edge & Carducci 2009 , Machens & Dralle 2015 . Extrathyroid extension was initially described as a poor prognostic factor in 1961 (Woolner et al. 1961) . Gross extrathyroid extension, classified as T4 since the first edition of AJCC, is a predictor of tumor recurrence and mortality (Sugitani et al. 2004 , Edge & Carducci 2009 , Ito et al. 2012 , Verburg et al. 2013 . Endocrine-Related Cancer (2017) 24, 221-226 
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Minimal extrathyroid extension (MEE) was introduced to the staging system at 2002, the sixth edition of AJCC. MEE includes extension to sternothyroid muscle or perithyroid soft tissue and is classified as T3 and consequently, upstages T1 and T2 differentiated thyroid cancer (DTC) patients aged older than 45 years to stage III disease (Edge & Carducci 2009 ). Upstaging appears to affect the decisions involving the extent of resection and radioactive iodine therapy (RAI) (Haugen et al. 2016 , Ruel et al. 2016 . Impact of MEE on the survival is a controversial topic and was investigated by different single institution studies mostly from Asia (Ito et al. 2006a ,b, Hotomi et al. 2012 , Shin et al. 2013 . Herein, the study sought to investigate the impact of MEE on survival in DTC patients aged older than 45 years and N0 in relation to the size of concomitant thyroid tumor.
Methods
The study is a retrospective cohort analysis utilizing the National Cancer Data Base (NCDB), 2004-2012. The NCDB is a joint program of the Commission on Cancer of the American College of Surgeons (ACS) and the American Cancer Society. The NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical surveillance resource oncology data set that currently captures 70% of all newly diagnosed malignancies in the United States annually. The NCDB is de-identified data that are exempted from approval of the institutional review board ((https://www.facs.org/quality-programs/ cancer/ncdb) Accessed October 15, 2015).
The primary study objective is to assess the impact of tumor size and MEE on the overall survival in patients with DTC. The secondary study objective is to assess the 
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survival benefit of total thyroidectomy vs lobectomy and utilization of RAI vs no utilization in patients with MEE. We focused on the group < 4 cm as these may not receive aggressive surgery or RAI treatment based on their size (unless MEE is judged significant and warranting such aggressive treatment) based on the most recent American Thyroid Association (ATA) guidelines (Haugen et al. 2016 ).
The study population included adult patients (age ≥ 45 years) who underwent thyroidectomy and had a diagnosis DTC based on International Classification of Diseases for Oncology third edition 8260, 8340, 8341, 8342, 8343, 8344, 8330, 8331, 8332, 8335, 8450) . Subsequently, the study population classified into control who had a pathological stage of pT2N0M0 (Group 1) and cases who had a pathological stage of pT3N0M0 as coded by the database based on pathological examination. Tumor size of 4 cm was further used to categorize cases into ≤ 4 cm with MEE (Group 2), > 4 cm with MEE (Group 3) and > 4 cm without MEE (Group 4). The choice of this cutoff value is based on the American Joint Committee on Cancer (AJCC 7th edition) Staging System (Edge & Carducci 2009 ).
Other independent factors that were considered for their confounding effect included: age (45 to < 65, ≥ 65), gender, race (white, black, Hispanic and other), Charlson/Deyo comorbidity score as coded by the database (0, 1 and ≥ 2), hospital volume classification followed quartile classification based on the total number of thyroidectomies performed per year (low: ≤ 25th percentile: 1-9 thyroidectomies/year, intermediate: > 25th to ≤ 75th percentile: 10-42 thyroidectomies/year and high: > 75th percentile: ≥ 43 thyroidectomies/year) and type of insurance as coded in the database (none, private, Medicaid, Medicare and other governmental).
Chi-square test was used to compare the baseline characteristics among the study groups. Kaplan-Meier curve and log-rank test were used to assess the association of each independent risk factor for the overall survival, and factors with significant association were considered confounders and were included in the multivariate model. Cox hazard ratio model was used to assess the time interaction term and calculate adjusted hazard ratio (HR) and 95% confidence interval (95% CI). Significant level was set as P = 0.05. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA.).
Results
A total of 9556 patients were included in our study, 4410 patients in Group 1 (T ≤ 4 cm without MEE), 3274 in Group 2 (T ≤ 4 cm with MEE) and 447 in Group 3 (T > 4 cm with MEE) and 1430 patients in Group 4 (T > 4 cm without MEE).
Most of the study population were white (85.5%), female (73.5%) and had private insurance (67.2%). Most patients did not have other comorbidities at the time of admission (81.7%) (Table 1) .
Median follow-up time was 46.7 months (interquartile range: 27.8-72.1). After adjusting for patient age, gender, race, Charlson/Deyo score, type of thyroidectomy, RAI therapy status, hospital volume and insurance type, the presence of MEE in Group 2 (T ≤ 4 cm with MEE) did not compromise the survival compared to Group 1 (T ≤ 4 cm without MEE) (HR: 0.98, 95% CI: (0.77-1.24), P = 0.85), suggesting no effect on survival in tumors less than 4 cm. Although their counterparts in Groups 3 and 4 (T > 4 cm with MEE) (T > 4 cm without MEE) had significantly lower survival in comparison with the same patients in Group 1 (T ≤ 4 cm without MEE) (HR: 2.44, 95% CI: (1.80, 3.32), P < 0.001) (HR: 1.65, 95% CI: (1.28, 2.14), P < 0.001) ( Fig. 1 and Table 2 ). Comparing 95% CIs showed that Groups 3 and 4 have lower survival compared to Group 2 and also showed that there is an overlap between Groups 3 and 4 95% CIs, which indicates no significant difference in survival between the two groups. Total thyroidectomy was the preferred operation performed by surgeons in the United States compared to unilateral thyroidectomy in all four groups (P ≤ 0.001). In comparison with unilateral thyroidectomy, total thyroidectomy was associated with improved overall survival in Group 4 only (T > 4 cm without MEE) (P = 0.01) (Table 3 ). However, RAI administration was 
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associated with improved survival in tumors larger than 4 cm in Group 3 (T > 4 cm with MEE) (HR: 0.57, 95% CI: (0.33-0.97), P = 0.0387) and in Group 4 (T > 4 cm without MEE) (HR: 0.58, 95% CI: (0.38-0.87), P = 0.008) ( Table 3 ).
Discussion
Our results demonstrated that MEE of DTC is not a poor prognostic factor in most thyroid cancer patients. MEE does not influence survival in DTC patients older than 45 years, with ≤4 cm and N0. To our knowledge, this is the largest series to investigate the impact of MEE on survival in this group of patients. This finding is especially important given the less aggressive approach to tumors less than 4 cm recommended by the most recent ATA thyroid cancer guidelines (Haugen et al. 2016) . The finding of MEE in this population should not lead to more aggressive surgical or RAI treatment.
Other recent studies agree with our findings and support the drop of MEE in the awaited 8th edition of the American Joint Committee on Cancer (AJCC) staging system (Table 4) (Amin et al. 2017 ). These were all retrospective single institution studies (Ito et al. 2006b , Chereau et al. 2014 , Hay et al. 2016 , except for Hotomi and coworkers, which was a prospective study including 930 Japanese patients (Hotomi et al. 2012) .
Historically, Mazaferri recommended that total thyroidectomy decreases the risk of recurrence compared to thyroid lobectomy and possibly improve survival (Mazzaferri et al. 1977 , Mazzaferri & Young 1981 .
Our study showed that surgeons in the United States performed more total thyroidectomy than lobectomy for these patients. Our findings demonstrated survival improvement with total thyroidectomy for some tumors over 4 cm. There was no survival improvement with total thyroidectomy for any tumors under 4 cm in our study. These findings again support the recent ATA thyroid cancer guidelines suggesting less aggressive treatment is warranted in this patient population with DTC less than 4 cm (Haugen et al. 2016 ).
MEE appears to affect the decisions involving the extent of resection and RAI adjuvant treatment in the United States (Haugen et al. 2016) . In our study, total thyroidectomy was more likely to be performed in Group 2 (T ≤ 4 cm with MEE) than that in Group 1 (T ≤ 4 cm without MEE). Only 4 studies did question the modality of treatment between the 2 groups (Moon et al. 2011 , Nixon et al. 2011 , Shin et al. 2013 , Radowsky et al. 2014 . Similar to Nixon, we demonstrated that total thyroidectomy was not associated with better survival in Group 2 (T ≤ 4 cm with MEE) (Nixon et al. 2011) .
We demonstrated that MEE with small tumor size ≤4 cm (Group 2) did not have any greater risk of mortality when compared with Stage II patients in (Group 1). However, in patients with large tumors >4 cm (Groups 3 and 4), overall survival was significantly affected.
Our study has limitations, some of which are anticipated with the use of any administrative database, which allows the potential for coding error. Information regarding disease-specific survival data is not available in NCDB. Nonetheless, the data have several strengths including the large sample size and specific details regarding clinical and pathological features. We recognize a further issue is that pathologic definition of minimal extrathyroidal extension may vary from pathologist to pathologist. We also recognize that our findings only apply to patients aged older than 45 years. Furthermore, we cannot explain why total thyroidectomy appeared to improve survival only in Group 4 but not in Group 3. It is of note, however, that RAI improves survival in all patients with large tumors greater than 4 cm.
Conclusions
Patients with DTC aged older than 45 years of age associated with MEE, and tumor size ≤4 cm, had similar survival of patients with Stage II. Total thyroidectomy did not add any survival benefit in this group. Our data support re-evaluation of the current ATA risk stratification and AJCC staging systems. The ATA risk stratification should consider stratification of the MEE into 2 groups: MEE with small size nodule ≤ 4 in the lowrisk group and MEE with large size nodule >4 cm in the intermediate-risk group. Accordingly, physicians should not over treat Stage II (DTC) associated with MEE by completion thyroidectomy and RAI ablation.
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